KESONOTIDE™ and ALPHA-D3

A new class of chemotherapy for cancer and chronic fibrotic diseases based on EGFR degradation/ vimentin inhibition actions. A ‘master blocker’ of protein response to inflammation.

This primary role of these two drug candidates is to inhibit the epithelial-mesenchymal transition (EMT) process, a process critically important to cancer progression and to the development of chronic fibrotic diseases and doing so largely independent of mutations affecting EGFR.

The cancers being targeted are all forms of solid cancer including epithelial cancers (eg, carcinomas of the lung, breast, prostate, ovary, pancreas, bowel, brain) and mesenchymal cancers (sarcomas).

Both KESONOTIDE and ALPHA-D3 are being compared for their relative efficacies across different cancer types.

Chronic fibrotic diseases are a secondary indication under investigation, particularly those affecting the kidney and liver.